

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: **Susanne Alenfalk et al.**

Confirmation No: **9947**

Patent No: **7,871,998**

Group Art Unit: **1624**

Issued: **January 18, 2011**

Examiner: **Mark L. Berch**

For: **Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity**

***FILED VIA EFS WEB***

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. §1.322**

Dear Sir:

In accordance with 37 C.F.R. 1.322, Patentee requests correction of the Office (errors) in the above-referenced patent as noted below:

1. Please replace claim 5 as follows (col. 126, lines 34-36):

-- A compound according to claim 2, wherein:

$R^3$  is hydrogen, methyl, chlorine, fluorine,  $C_{1-6}$  alkylS-, or methoxy.--.

Support for the request for entry of the replacement claim can be found in the response to final office action dated May 17, 2010 (previously claim 6).

2. Col. 127, claim 8, please replace lines 64-66 with the following:

--N-({4-[(2R,3R)-1-(4-Fluorophenyl)-3-({2-hydroxy-2-[4-(methylthio)phenyl]ethyl}thio)-4-oxoazetidin-2-yl]phenoxy}acetyl)glycyl-3-methyl-D-valine;--

Support for the request for entry of the replacement of the partial claim can be found in the response to final office action dated May 17, 2010 (previously claim 11).

Applicants respectfully request favorable action.

The Commissioner is hereby authorized to charge any deficiencies of fees and credit of any overpayments to Deposit Account No. 50-0436.

Respectfully submitted,

/Paul K. Legaard, Reg. No. 38534/

Paul K. Legaard

Registration No. 38534

Date: April 4, 2011

Pepper Hamilton LLP  
400 Berwyn Park  
899 Cassatt Road  
Berwyn, PA 19312  
Tel: 610.640.7859  
Fax: 610.640.7835